Access and benefit-sharing following the synthesis of horsepox virus

No Thumbnail Available
File version
Author(s)
Rourke, Michelle F
Phelan, Alexandra
Lawson, Charles
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
License
Abstract

To the editor — In January 2018, PLOS ONE published the chemical synthesis of horsepox virus (HPXV) by a group of privately funded Canadian researchers. The authors state that “[s]ince HPXV may be extinct and the only specimen of HPXV that has been identified is unavailable for investigation, we explored whether HPXV could be obtained by large-scale gene synthesis.”1 The DNA sequence of the HPXV genome was published2 in 2006 and is publicly available in the US National Institutes of Health GenBank database. The Canadian researchers used the HPXV genome sequence as the digital template to ‘rematerialize’ the virus using DNA fragments ordered from a commercial provider in Germany. Viruses from the genus Orthopox have particular genetic structures (like terminal hairpin loops) that make them difficult to both sequence and reverse engineer, but the Canadian group overcame such technical difficulties using a helper virus, recreating a “faithful copy” of the HPXV template1.

Journal Title

Nature Biotechnology

Conference Title
Book Title
Edition
Volume

38

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Medical biotechnology

Synthetic biology

Environmental and resources law

International and comparative law

Persistent link to this record
Citation

Rourke, MF; Phelan, A; Lawson, C, Access and benefit-sharing following the synthesis of horsepox virus., Nature Biotechnology, 2020, 38, pages 537–539.

Collections